<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02987140</url>
  </required_header>
  <id_info>
    <org_study_id>201606057RINA</org_study_id>
    <nct_id>NCT02987140</nct_id>
  </id_info>
  <brief_title>Understand FoG in PD: Behavioral Physiology and Clinical Application</brief_title>
  <official_title>Understand Freezing of Gait in Parkinson's Disease: Behavioral Physiology and Clinical Application</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Taiwan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goals of this proposed study are to investigate the behavioral and&#xD;
      neurophysiological mechanisms of patients with Parkinson's disease (PD) experiencing freezing&#xD;
      of gait (FoG). More specifically, we aim to determine the behavioral changes in&#xD;
      context-dependency and changes in corticomotor excitability associated with FoG.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Freezing of gait (FoG) is a debilitating symptom for patients with Parkinson's&#xD;
      disease (PD). FoG not only impairs walking but also significantly increase fall risks and&#xD;
      decrease quality of life for patients with PD. Despite the critical consequences, the&#xD;
      mechanisms associated with this phenomenon are not well understood.&#xD;
&#xD;
      Clinically, FoG often occurs when individuals with PD are approaching a narrow pathway or&#xD;
      crossing a busy street. This observation leads to the hypothesis that FoG is associated with&#xD;
      context-dependent motor performance, a phenomenon that an individual demonstrate poorer&#xD;
      performance if the learned motor task is carried out in an unfamiliar context. Whether the&#xD;
      occurrence of freezing episodes is a result of context-dependency has not been systematically&#xD;
      investigated. Moreover, the changes in corticomotor excitability associated with FoG have not&#xD;
      been well-established.&#xD;
&#xD;
      Objectives: The objectives of this proposal are to understand the behavioral and&#xD;
      neurophysiological mechanisms of FoG. The specific aim is to examine the behavioral changes&#xD;
      in context-dependency and changes in corticomotor excitability associated with FoG.&#xD;
&#xD;
      Methods: a total of 70 participants, including PD patients with FoG, PD patients without FoG,&#xD;
      and age-matched non-disabled adults, will be recruited. The participants will undergo&#xD;
      behavioral and neurophysiological examinations. Behavioral evaluations will include&#xD;
      context-dependent motor performance, FoG, disease severity, and walking and balance&#xD;
      functions. Transcranial magnetic stimulation and electroencephalogram will be used to measure&#xD;
      corticomotor excitability of the participants. Analysis of variance (ANOVA) and regression&#xD;
      analysis will be performed to compare and determine the relationship between FoG, behavioral&#xD;
      outcomes, and corticomotor excitability. Statistical significance level is set at p &lt; 0.05.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New Freezing of Gait Questionnaire (NFOG-Q)</measure>
    <time_frame>30 mins</time_frame>
    <description>The New Freezing of Gait Questionnaire (NFOG-Q) will be used to evaluate the freezing frequency and severity of the patients with PD. It composes of 3 parts; in the first part, a video clip will be shown to the participants with PD and help to classify whether an individual is a freezer or non-freezer. The second and third part of the questionnaire is designed for freezers only. PartⅡassesses the severity of FoG according to the frequency and duration of the freezing episodes, while PartⅢevaluates the impact of freezing on daily activities, such as walking. The reliability and internal consistency of the NFOG-Q have been well-established for patients with PD (Nieuwboer et al., 2009).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Context-dependent behavior</measure>
    <time_frame>40 mins</time_frame>
    <description>A modified finger sequence task is specifically designed to evaluate context-dependent behavior for patients with PD. The participants will be instructed to put their index and middle fingers of both hands on a designated location of an enlarged key-board.&#xD;
The participants will first practice the three sequences for a total of 324 practice trials on the first day. Ten minutes and 24 hours after practice, to control for the medication status, the participants will be tested under the SAME and SWITCH conditions.With these 2 testing conditions, we will be able to calculate a variable called Switch Cost, which is the performance difference between the SWTICH and the SAME conditions normalized by the SAME condition [100% * (SWITCH - SAME)/SAME]. The Switch Cost will be used as an indicator of context-dependency.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>30 mins</time_frame>
    <description>The UPDRS contains 4 sections, and PartIIIwill be used in this study to evaluate the motor disturbances of patients with PD. Excellent internal consistency and validity has been established for UPDRS (Goetz et al., 2008).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Montreal Cognitive Assessment (MoCA)</measure>
    <time_frame>10 mins</time_frame>
    <description>The MoCA evaluates several cognitive domains, including visuospatial processing, naming, short-term memory, digit forward and backward span, verbal fluency, abstract concept, counting, and orientation. The MoCA has been found to be a valid and reliable tool to screen for cognitive dysfunctions in patients with PD (Gill, Freshman, Blender, &amp; Ravina, 2008).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Stroop Color-Word test</measure>
    <time_frame>5 mins</time_frame>
    <description>The Stroop Color-Word test involves congruent and incongruent conditions.The goal of the participants is to read out the ink color of the word, but not the color word name itself, as accurately and as soon as possible (Dubois et al., 2007; Ridley, Johnson, &amp; Braisted, 1978).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>10-Meter Walk Test (10MWT)</measure>
    <time_frame>5 mins</time_frame>
    <description>10MWT assesses the walking ability of the participants. The participants will be instructed to walk in their comfortable walking speed and their fastest walking speed for 10 meters. Gait speed, stride length, and cadence will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Timed Up and Go (TUG) test</measure>
    <time_frame>5 mins</time_frame>
    <description>The TUG evaluates the balance ability of the participants. The participants will be seated on a comfortable chair with hip and knee flexed at 90 Upon a 'Go' signal, the participants will stand up from the chair, walk 3 meters, turn around, and sit back down to the chair. The time to complete the procedure will be measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Parkinson's Disease Questionnaire(PDQ-39)</measure>
    <time_frame>10 mins</time_frame>
    <description>The PDQ-39 specifically assess quality of life in patients with PD. PDQ-39 contains 39 questions embedded in 8 different domains. PDQ-39 has now become the most widely accepted and reliable measure to determine the overall health status for patients with PD (Jenkinson, Peto, Fitzpatrick, Greenhall, &amp; Hyman, 1995).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transcranial magnetic stimulation</measure>
    <time_frame>45 mins</time_frame>
    <description>To compare the neurophysiological characteristics of PD patients with FoG, PD patients without FoG, and non-disabled adults, a TMS device (The Magstim Company Ltd, Whitland, UK) will be used. TMS outcomes will include resting motor threshold (RMT), motor evoked potentials (MEPs), cortical silent period (CSP), short-interval intracortical inhibition (SICI), long-interval intracortical inhibition (LICI), and intracortical facilitation (ICF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electroencephalogram (EEG)</measure>
    <time_frame>40 mins</time_frame>
    <description>While performing the modified finger sequence task, the electroencephalogram (EEG) will be used to monitor and record brain activity. Comparisons will be made between the first block of practice, last block of practice, and the two testing conditions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The short FoG and festination assessment score</measure>
    <time_frame>20 mins</time_frame>
    <description>The short FoG and festination assessment score, developed by Ziegler and colleagues (2010), will be used to clinically assess freezing and festination episodes over a short time course. The participants will initially sit on a chair for 30 seconds, then they will be instructed to stand up and walk to a floor mark with 40 radius and make 360 turn clockwise and counter-clockwise. Then, the participants will walk through a door, turn around and walk back to the chair. The participants will be required to walk in a fast but safe speed. This evaluation approach has been demonstrated to be feasible and reliable for assessing the severity of freezing and festination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Parkinson Disease</condition>
  <condition>Freezing of Gait</condition>
  <arm_group>
    <arm_group_label>PD+FoG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PD patients with FoG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PD-FoG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>PD patients without FoG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>age-matched non-disabled adults</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Clinical evaluations</intervention_name>
    <description>Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>PD+FoG</arm_group_label>
    <arm_group_label>PD-FoG</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Individuals with Parkinson's disease&#xD;
&#xD;
          -  Healthy control subjects&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  unable to follow the instructions&#xD;
&#xD;
          -  have other neurological diseases other than PD&#xD;
&#xD;
          -  have pacemaker implanted in their body&#xD;
&#xD;
          -  have a history of seizure&#xD;
&#xD;
          -  have a family history of epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ya-Yun Lee, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ya-Yun Lee, PHD</last_name>
    <phone>886-2-33668155</phone>
    <email>yayunlee@ntu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ya-Yun Lee, PHD</last_name>
      <phone>02-33668155</phone>
      <email>yayunlee@ntu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <study_first_submitted>December 6, 2016</study_first_submitted>
  <study_first_submitted_qc>December 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2016</study_first_posted>
  <last_update_submitted>December 6, 2016</last_update_submitted>
  <last_update_submitted_qc>December 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Parkinson's disease</keyword>
  <keyword>freezing of gait</keyword>
  <keyword>context-dependency</keyword>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>visual cues</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>December 24, 2017</submitted>
    <returned>September 20, 2018</returned>
    <submitted>September 27, 2018</submitted>
    <returned>February 15, 2019</returned>
    <submitted>February 18, 2019</submitted>
    <returned>May 31, 2019</returned>
    <submitted>June 3, 2019</submitted>
    <returned>July 26, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02987140
org study id: 201606057RINA
nct id: NCT02987140
lead sponsor: 
collaborator: 
has dmc: No
The overall goals of this proposed study are to investigate the behavioral and
      neurophysiological mechanisms of patients with Parkinson's disease (PD) experiencing freezing
      of gait (FoG). More specifically, we aim to determine the behavioral changes in
      context-dependency and changes in corticomotor excitability associated with FoG.
Background: Freezing of gait (FoG) is a debilitating symptom for patients with Parkinson's
      disease (PD). FoG not only impairs walking but also significantly increase fall risks and
      decrease quality of life for patients with PD. Despite the critical consequences, the
      mechanisms associated with this phenomenon are not well understood.

      Clinically, FoG often occurs when individuals with PD are approaching a narrow pathway or
      crossing a busy street. This observation leads to the hypothesis that FoG is associated with
      context-dependent motor performance, a phenomenon that an individual demonstrate poorer
      performance if the learned motor task is carried out in an unfamiliar context. Whether the
      occurrence of freezing episodes is a result of context-dependency has not been systematically
      investigated. Moreover, the changes in corticomotor excitability associated with FoG have not
      been well-established.

      Objectives: The objectives of this proposal are to understand the behavioral and
      neurophysiological mechanisms of FoG. The specific aim is to examine the behavioral changes
      in context-dependency and changes in corticomotor excitability associated with FoG.

      Methods: a total of 70 participants, including PD patients with FoG, PD patients without FoG,
      and age-matched non-disabled adults, will be recruited. The participants will undergo
      behavioral and neurophysiological examinations. Behavioral evaluations will include
      context-dependent motor performance, FoG, disease severity, and walking and balance
      functions. Transcranial magnetic stimulation and electroencephalogram will be used to measure
      corticomotor excitability of the participants. Analysis of variance (ANOVA) and regression
      analysis will be performed to compare and determine the relationship between FoG, behavioral
      outcomes, and corticomotor excitability. Statistical significance level is set at p < 0.05.
allocation: Randomized
intervention model: Factorial Assignment
primary purpose: Screening
masking: Single (Outcomes Assessor)
measure: New Freezing of Gait Questionnaire (NFOG-Q)
time frame: 30 mins
description: The New Freezing of Gait Questionnaire (NFOG-Q) will be used to evaluate the freezing frequency and severity of the patients with PD. It composes of 3 parts; in the first part, a video clip will be shown to the participants with PD and help to classify whether an individual is a freezer or non-freezer. The second and third part of the questionnaire is designed for freezers only. PartⅡassesses the severity of FoG according to the frequency and duration of the freezing episodes, while PartⅢevaluates the impact of freezing on daily activities, such as walking. The reliability and internal consistency of the NFOG-Q have been well-established for patients with PD (Nieuwboer et al., 2009).
measure: Context-dependent behavior
time frame: 40 mins
description: A modified finger sequence task is specifically designed to evaluate context-dependent behavior for patients with PD. The participants will be instructed to put their index and middle fingers of both hands on a designated location of an enlarged key-board.
The participants will first practice the three sequences for a total of 324 practice trials on the first day. Ten minutes and 24 hours after practice, to control for the medication status, the participants will be tested under the SAME and SWITCH conditions.With these 2 testing conditions, we will be able to calculate a variable called Switch Cost, which is the performance difference between the SWTICH and the SAME conditions normalized by the SAME condition [100% * (SWITCH - SAME)/SAME]. The Switch Cost will be used as an indicator of context-dependency.
measure: The Unified Parkinson's Disease Rating Scale (UPDRS)
time frame: 30 mins
description: The UPDRS contains 4 sections, and PartIIIwill be used in this study to evaluate the motor disturbances of patients with PD. Excellent internal consistency and validity has been established for UPDRS (Goetz et al., 2008).
measure: Montreal Cognitive Assessment (MoCA)
time frame: 10 mins
description: The MoCA evaluates several cognitive domains, including visuospatial processing, naming, short-term memory, digit forward and backward span, verbal fluency, abstract concept, counting, and orientation. The MoCA has been found to be a valid and reliable tool to screen for cognitive dysfunctions in patients with PD (Gill, Freshman, Blender, & Ravina, 2008).
measure: The Stroop Color-Word test
time frame: 5 mins
description: The Stroop Color-Word test involves congruent and incongruent conditions.The goal of the participants is to read out the ink color of the word, but not the color word name itself, as accurately and as soon as possible (Dubois et al., 2007; Ridley, Johnson, & Braisted, 1978).
measure: 10-Meter Walk Test (10MWT)
time frame: 5 mins
description: 10MWT assesses the walking ability of the participants. The participants will be instructed to walk in their comfortable walking speed and their fastest walking speed for 10 meters. Gait speed, stride length, and cadence will be calculated.
measure: The Timed Up and Go (TUG) test
time frame: 5 mins
description: The TUG evaluates the balance ability of the participants. The participants will be seated on a comfortable chair with hip and knee flexed at 90 Upon a 'Go' signal, the participants will stand up from the chair, walk 3 meters, turn around, and sit back down to the chair. The time to complete the procedure will be measured.
measure: The Parkinson's Disease Questionnaire(PDQ-39)
time frame: 10 mins
description: The PDQ-39 specifically assess quality of life in patients with PD. PDQ-39 contains 39 questions embedded in 8 different domains. PDQ-39 has now become the most widely accepted and reliable measure to determine the overall health status for patients with PD (Jenkinson, Peto, Fitzpatrick, Greenhall, & Hyman, 1995).
measure: Transcranial magnetic stimulation
time frame: 45 mins
description: To compare the neurophysiological characteristics of PD patients with FoG, PD patients without FoG, and non-disabled adults, a TMS device (The Magstim Company Ltd, Whitland, UK) will be used. TMS outcomes will include resting motor threshold (RMT), motor evoked potentials (MEPs), cortical silent period (CSP), short-interval intracortical inhibition (SICI), long-interval intracortical inhibition (LICI), and intracortical facilitation (ICF).
measure: Electroencephalogram (EEG)
time frame: 40 mins
description: While performing the modified finger sequence task, the electroencephalogram (EEG) will be used to monitor and record brain activity. Comparisons will be made between the first block of practice, last block of practice, and the two testing conditions.
measure: The short FoG and festination assessment score
time frame: 20 mins
description: The short FoG and festination assessment score, developed by Ziegler and colleagues (2010), will be used to clinically assess freezing and festination episodes over a short time course. The participants will initially sit on a chair for 30 seconds, then they will be instructed to stand up and walk to a floor mark with 40 radius and make 360 turn clockwise and counter-clockwise. Then, the participants will walk through a door, turn around and walk back to the chair. The participants will be required to walk in a fast but safe speed. This evaluation approach has been demonstrated to be feasible and reliable for assessing the severity of freezing and festination.
arm group label: PD+FoG
arm group type: Experimental
description: PD patients with FoG
arm group label: PD-FoG
arm group type: Active Comparator
description: PD patients without FoG
arm group label: Control
arm group type: Active Comparator
description: age-matched non-disabled adults
intervention type: Behavioral
intervention name: Clinical evaluations
description: Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
arm group label: Control
arm group label: PD+FoG
arm group label: PD-FoG
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: Accepts Healthy Volunteers
last name: Ya-Yun Lee, PHD
role: Principal Investigator
affiliation: National Taiwan University
last name: Ya-Yun Lee, PHD
phone: 886-2-33668155
email: yayunlee@ntu.edu.tw
facility: 
status: Recruiting
contact: 
country: Taiwan
responsible party type: Sponsor
mesh term: Parkinson Disease
submitted: December 24, 2017
returned: September 20, 2018
submitted: September 27, 2018
returned: February 15, 2019
submitted: February 18, 2019
returned: May 31, 2019
submitted: June 3, 2019
returned: July 26, 2019